Traws Pharma (TRAW) director reports equity awards details in Form 4 filing

Rhea-AI Filing Summary

Traws Pharma, Inc. director Mary Teresa Shoemaker reported equity awards dated 12/12/2025. She received 6,157 restricted stock units of common stock at a reported price of $0, leaving her with 6,292 common shares beneficially owned directly after the transaction. The filing states these restricted stock units will vest 100% on the first anniversary of the grant date, with each unit converting into one share of common stock. She was also granted a stock option for 24,629 shares of common stock at an exercise price of $2.33 per share, which becomes exercisable on 12/12/2026 and expires on 12/12/2035, and was reported as acquired at a price of $0.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shoemaker Mary Teresa

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		6,157(1)	A	$0	6,292	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to purchase)	$2.33	12/12/2025		A		24,629		12/12/2026(2)	12/12/2035	Common Stock	24,629	$0	24,629	D

Explanation of Responses:

1. Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

2. The options vest 100% on the first anniversary of the grant date.

	/s/ Mary Teresa Shoemaker	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Traws Pharma (TRAW) report in this Form 4?

The filing reports that director Mary Teresa Shoemaker received equity awards in Traws Pharma, Inc. on 12/12/2025, including restricted stock units and stock options tied to the company’s common stock.

How many restricted stock units did the TRAW director receive and when do they vest?

The director received 6,157 restricted stock units of Traws Pharma common stock. The filing states that these units will vest 100% on the first anniversary of the grant date, and each unit converts into one share of common stock.

What stock options were granted to the Traws Pharma (TRAW) director?

The director was granted a stock option to purchase 24,629 shares of Traws Pharma common stock at an exercise price of $2.33 per share. The option was reported as acquired on 12/12/2025.

When do the new TRAW stock options become exercisable and when do they expire?

The stock options become exercisable on 12/12/2026 and have an expiration date of 12/12/2035, giving the director the right to purchase up to 24,629 shares during that period at the stated exercise price.

How many Traws Pharma shares does the director own after these transactions?

After the reported restricted stock unit award, the director beneficially owns 6,292 shares of Traws Pharma common stock directly, as disclosed in the Form 4.

Did the TRAW director pay for the restricted stock units or options at grant?

The Form 4 lists a price of $0 for both the 6,157 restricted stock units and the 24,629 stock options at the time of grant, while the options carry a separate $2.33 per share exercise price for future purchases.